Welcome to SITC Researcher Resources page, featuring scientific resources on specific topics in cancer immunotherapy. Click on a topic below to discover related resources.
VIEW ALL RESOURCES
Research Article: “Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes”
Research Article: “CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency"
This two-day workshop, hosted in September 2019, brought together cancer immunotherapy experts to discuss and address challenges concerning the use and development of adoptive cellular therapies for the treatment of cancer patients.
Research Article: “A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors"
Research Article: “Phase 2 study of pembrolizumab in patients with advanced rare cancers"
Research Article: “The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a"
Research Article: "Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma"
The SITC Cytokines in Cancer Immunotherapy Workshop is a two-day program focusing on providing a deeper understanding of cytokines in immune cell proliferation, differentiation, and function, as they pertain to tumor immunobiology and cancer immunotherapy approaches.
Program details coming soon!
JITC Collection: “Immune Checkpoints Beyond PD-1”
Case Report: “Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab"
Case Report: “A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab"
This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundation knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.
This pre-conference program outlined funding opportunities and how to navigate those, address critical points of government and private sector grant submissions, and gave attendees the tools to identify points that determine the success or failure of a grant proposal, helping them to optimize the process of grant re-submission.*Access restrictions may apply to presentations and recordings.
Date: Monday, December 7, 2020 Time: 2:00-3:00 p.m. ET
This one-hour webinar, moderated by Chris Langsdorf (Thermo Fisher Scientific), and presented by Jennifer Gao, MD (FDA) and Kathryn Lurain, MD, MPH (NCI), will discuss the various career paths and opportunities available in government. This webinar, intended for early career scientists, will also feature a Q&A session where attendees can connect with these experts in the field.
Research Article: “Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors”
Case Report: “PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response”JITC Collections: Immune Monitoring Technology Primers
Section 1: Basic Principles of Tumor Immunology
Chapter 4: HLA Class I Antigen- Processing Machinery in Cancer
Section V: Regulatory Aspects of Cancer Immunotherapy
Chapter 55: Regulatory Considerations for In Vitro Diagnostic Devices
These guidelines are developed according to an expert committee, who addresses knowledge gaps in our understanding of immunotherapy treatments, and develops evidence-based recommendations by evaluating the published literature and providing their opinions on key issues, documenting alternative opinions when they occur.
Guidelines: “Immune Checkpoint Inhibitors & Cytokine-Related Adverse Events”
Guidelines: “Immune Effector Cell-Related Adverse Events”
Research Article: “Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma"
Research Article: “Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer"
Research Article: “Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis"
Research Article: “HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma"
Review: “High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation"
Chapter 16: Manipulating Innate immune Pathways as Cancer Immunotherapy
Chapter 17: Cancer Vaccines: Considerations of Antigen, Formulation, and Deliver
Chapter 18: T Cell Modulatory Cytokines
Session II: Transcriptional Patterns of Distinct Immune Landscapes
Session III: Therapeutic Interventions to Modify the Cancer Microenvironment and Related Experimental Systems for Validation
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com